

Figure 1




Figure 2




Figure 3





Figure 4

A



IM9: B lymphoblast

BL2: Burkitt's lymphoma

CEM: T cell leukemia

Karpas 299: T cell lymphoma

Sup-M2: ALCL

UCONN: ALCL

(ALCL: Anaplastic large-cell lymphoma)

DAUDI: Burkitt's lymphoma

Ramos: Burkitt's lymphoma

BJAB: Burkitt's lymphoma

HD-MYZ: Hodgkin lymphoma



KM-H2: Hodgkin lymphoma

L428: Hodgkin lymphoma

Jurkat: T cell leukemia

Figure 4

B



IM9: B lymphoblast	DAUDI: Burkitt's lymphoma
BL2: Burkitt's lymphoma	Ramos: Burkitt's lymphoma
CEM: T cell leukemia	BJAB: Burkitt's lymphoma
Karpas 299: T cell lymphoma	HD-MYZ: Hodgkin lymphoma
Sup-M2: ALCL	KM-H2: Hodgkin lymphoma
UCONN: ALCL	L428: Hodgkin lymphoma
(ALCL: Anaplastic large-cell lymphoma)	Jurkat: T cell leukemia

Figure 5

**Effectiveness of NMT inhibitors on Burkitt's Lymphoma Cell Line
Ramos in comparison to immortalized normal B lymphocytic cell
line (IM9) after 48 Hours at different concentrations**




Figure 6






Figure 7



IM9: B lymphoblast
 BL2: Burkitt's lymphoma
 Ramos: Burkitt's lymphoma
 DLCL: Diffuse large B-cell lymphoma
 FL: Follicular lymphoma

Figure 8


A



NMT-1 stain. Upper row: N1, N2 normal lymph nodes, Neg Negative control. Middle row: three Burkitt lymphoma cases (BL 1-3). Lower row: three DLBCL (LCL-1-3) cases. Both normal lymph nodes and lymphoma show strong stains. No difference observed.

Figure 8


B



NMT-2 stain. Upper row: N1, N2 normal lymph nodes, Neg Negative control. Middle row: three Burkitt lymphoma cases (BL 1-3). Lower row: three DLBCL (LCL-1-3). The normal lymph nodes show a strong stain whereas the Burkitt lymphoma (BL) and diffuse large B cell lymphoma (LCL) show a weak stain.

Figure 8

C



D




Figure 8




Figure 9




Figure 9

C






Figure 9

D



NeutrAvidin™-HRP 1:20,000

50 μ g protein per lane

Figure 9

E







Figure 10



A Figure 11



B





Figure 11

C


	Histological Subtype	Cell line	NMT2 Expression	Source
Haematopoietic or Lymphoid Source	Acute Myeloid Leukemia	EOL-1	3.6642	DSMZ
	Acute Myeloid Leukemia	GDM-1	3.7673	ATCC
	Acute Myeloid Leukemia	PL-21	4.0117	ATCC
	Acute Myeloid Leukemia	Kasumi-6	4.0205	ATCC
	Acute Myeloid Leukemia	MV-4-11	4.0953	HSRRB
	Acute Myeloid Leukemia	HL-60	4.3381	ATCC
	Acute Myeloid Leukemia	MOLM-13	4.3432	ATCC
	Acute Myeloid Leukemia	KO52	4.4048	DSMZ
	Acute Myeloid Leukemia	OCI-AML2	4.6291	DSMZ
	B Cell Lymphoma Unspecified	MC118	3.9043	ATCC
	B Cell Lymphoma Unspecified	RL	3.9759	ATCC
	B Cell Lymphoma Unspecified	JM1	4.0771	DSMZ
	B Cell Lymphoma Unspecified	NU-DUL-1	4.3577	DSMZ
	B Cell Lymphoma Unspecified	RI-1	4.6862	ATCC
	Blast Phase Chronic Myeloid Leukaemia	EM-2	4.1421	DSMZ
	Burkitt's Lymphoma	NAMALWA	3.8721	DSMZ
	Burkitt's Lymphoma	Daudi	3.9571	DSMZ
	Burkitt's Lymphoma	EB1	3.9797	ATCC
	Burkitt's Lymphoma	SU-DHL-10	3.9798	ATCC
	Burkitt's Lymphoma	BL-41	4.0698	ATCC
	Burkitt's Lymphoma	EB2	4.2023	ATCC
	Burkitt's Lymphoma	GA-10	4.2233	ATCC
	Burkitt's Lymphoma	P3HR-1	4.2434	ATCC
	Burkitt's Lymphoma	BL-70	4.4422	DSMZ
	Diffuse Large B Cell Lymphoma	OCI-LY-19	3.6244	ATCC
	Diffuse Large B Cell Lymphoma	DOHH-2	3.7235	ATCC
	Diffuse Large B Cell Lymphoma	WSU-DLCL2	3.8199	DSMZ
	Diffuse Large B Cell Lymphoma	SU-DHL-5	3.8819	DSMZ
	Diffuse Large B Cell Lymphoma	DB	3.9475	DSMZ
	Diffuse Large B Cell Lymphoma	SU-DHL-8	3.9527	DSMZ
	Diffuse Large B Cell Lymphoma	SU-DHL-6	3.9735	DSMZ
	Diffuse Large B Cell Lymphoma	KARPAS-422	4.4105	DSMZ
	Diffuse Large B Cell Lymphoma	SU-DHL-4	4.4221	DSMZ
	Plasma Cell Myeloma	PCM6	3.7393	ATCC
	Plasma Cell Myeloma	KHM-1B	4.0262	HSRRB
	Plasma Cell Myeloma	HuNS1	4.2789	DSMZ
	Plasma Cell Myeloma	L-363	4.4213	RIKEN
	Plasma Cell Myeloma	RPMI 8226	4.6537	ATCC
	Intestinal Adenocarcinoma	COLO 205	4.2498	ATCC
	Lung Mixed Adenosquamous Carcinoma	HCC-1195	4.3572	KCLB
	Lung Small Cell Carcinoma	NCI H2029	4.2394	ATCC
	Lung Unspecified	BEN	4.5409	DSMZ
	Oesophagus Squamous Cell Carcinoma	TE-4	4.0083	RIKEN
	Bone Unspecified	SK-N-MC	4.1437	ATCC
	Breast Ductal Carcinoma	UACC-893	3.8595	ATCC
	Breast Ductal Carcinoma	HCC202	4.59	ATCC
	Stomach Diffuse Adenocarcinoma	OCUM-1	4.5727	HSRRB
	Stomach Ductal Carcinoma	HCC1500	4.4632	ATCC
	Thyroid Medullary Carcinoma	TT	4.0649	ATCC
	Urinary Tract Transitional Cell Carcinoma	HT-1376	4.0436	ATCC

Figure 12


A



B



C



D





Figure 12

E



F





Figure 13

A

Purification of GST-NMT1 from *E. Coli*




B

Purification of GST-NMT2 from *E. Coli*



Figure 13

C



- Gel A: Purification of NMT1
- 1. All Blue marker
 - 2. Ni-NTA column pool
 - 3. Gel Filtration pool
 - 4. FT of Resource S
 - 5. Fraction 8 (f8)
 - 6. f16
 - 7. f18
 - 8. f19
 - 9. f20
 - 10. f21
 - 11. f22
 - 12. f41
 - 13. f42
 - 14. f66
 - 15. f67

Figure 13

D




Figure 14




Figure 15




Figure 16




Figure 17

A





Figure 17


B

mRNA expression level (RMA)



5.64

Figure 18



Affinity chromatography of desthiobiotinylated post-translationally myristoylated proteins from Jurkat T cells




Figure 19






Figure 20



WB: Neutravidin-HRP

Figure 21

A



B








Figure 22




Figure 23




Figure 24




Figure 25




Figure 26




Figure 27




Figure 28




Figure 29

--- + - -+ - - - + - +++++ ++-+ - - +
NMT1: PADESEITAVKFPAPPLPQMMEGNGNGHEHCSDQENEEDNSYNRGELSPANDTGAKKKKKKKKKKKKSGSETDSAQDQPVK
NMT2: WAEDSESAASQQLLELDQDTCGLDGDNEEETEHAKSPGGYLGA+++++KPKKKKKKPNSSGCTKSDSASDSQEIKIQGF
 == - - - - - + + +++++ ++++++ + - - - +

Figure 30




Figure 31




Figure 32




Figure 33




Figure 34




Figure 35




Figure 36




Figure 37




Figure 38




Figure 39




Figure 40





Figure 41

A.



B.




Figure 42

